<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Structure of the extended spectrum beta lactamase BES-1 Experiment number</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author>
							<persName><roleName>Dr</roleName><forename type="first">Raimond</forename><forename type="middle">B G</forename><surname>Ravelli</surname></persName>
							<affiliation key="aff0">
								<orgName type="laboratory" key="lab1">Laboratoire de bactériologie</orgName>
								<orgName type="laboratory" key="lab2">Laboratoire de bactériologie</orgName>
								<orgName type="laboratory" key="lab3">Laboratoire de bactériologie</orgName>
								<orgName type="laboratory" key="lab4">Laboratoire de bactériologie</orgName>
								<orgName type="institution" key="instit1">Clermont-Fd* Frédéric Robin</orgName>
								<orgName type="institution" key="instit2">Clermont-Fd* David Lesseyne</orgName>
								<orgName type="institution" key="instit3">Clermont-Fd Marlène Jan</orgName>
								<orgName type="institution" key="instit4">Clermont-Fd</orgName>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Pr</forename><forename type="middle">Richard</forename><surname>Bonnet</surname></persName>
							<affiliation key="aff0">
								<orgName type="laboratory" key="lab1">Laboratoire de bactériologie</orgName>
								<orgName type="laboratory" key="lab2">Laboratoire de bactériologie</orgName>
								<orgName type="laboratory" key="lab3">Laboratoire de bactériologie</orgName>
								<orgName type="laboratory" key="lab4">Laboratoire de bactériologie</orgName>
								<orgName type="institution" key="instit1">Clermont-Fd* Frédéric Robin</orgName>
								<orgName type="institution" key="instit2">Clermont-Fd* David Lesseyne</orgName>
								<orgName type="institution" key="instit3">Clermont-Fd Marlène Jan</orgName>
								<orgName type="institution" key="instit4">Clermont-Fd</orgName>
							</affiliation>
						</author>
						<title level="a" type="main">Structure of the extended spectrum beta lactamase BES-1 Experiment number</title>
					</analytic>
					<monogr>
						<imprint>
							<date/>
						</imprint>
					</monogr>
					<idno type="MD5">976B5B6B13670D1E8C0B1AC3D6FD8606</idno>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.8.2" ident="GROBID" when="2025-05-22T20:37+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<label type="revision">unknown</label>
					<label type="parameters">startPage=-1, endPage=-1, consolidateCitations=1, consolidateHeader=1, consolidateFunders=0, includeRawAffiliations=false, includeRawCitations=true, includeRawCopyrights=false, generateTeiIds=false, generateTeiCoordinates=[], flavor=null</label>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<abstract/>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Report:</head><p>Microbial resistance to β-lactams is one of the major problems facing health care institution, because of the wide use of these molecules. Structural data about extended-spectrum β-lactamases (enzymes able to cleave the beta-lactam ring by an acylation and hydrolytic deacylation catalytic mechanism) are particularly important for the conception of novel β-lactam antibiotics.</p><p>BES-1 is an atypical ESBL, which only share 47 % identity with CTX-M enzymes, which are the most closely related ESBL <ref type="bibr">(Bonnet et al., 2000)</ref>. BES-1 exhibits an unusual high activity against the two major wide spectrum β-lactams (ceftotaxime and ceftazidime) and a low susceptibility to the β-lactamase inhibitor tazobactam.</p><p>To investigate the structural features involved in the atypical activity of BES-1, we crystallized BES-1 and determined its three-dimensional structure at resolution of 1.5 Å (Figure <ref type="figure">1</ref>). Crystal structure revealed insights into the structure-function relationships of BES-1. BES-1 general structure was close to those of other βlactamases, especially a conserved disposition of the catalytic residues (Ser70, Ser130, Glu166). However, BES-1 also presented specificities. The Ω loop located at the entrance of the active site had an atypical positioning. In the Ω loop, Cα atoms of residues 167 to 179, which is probably implicated in the substrate recognition, shifted 0.6 to 1.5 Å in comparison with the structure of β-lactamases TEM-1 and CTX-M-9 (Figure <ref type="figure">2</ref>). We also noticed a 0.8 Å shift of the β3 strand (Figure <ref type="figure">3</ref>). On the other site of the active site, the loop between residues 101 to 106 presented an original conformation and induced a 1.2 to 2 Å shift of Ala104 away from the active site (Figure <ref type="figure">4</ref>). This important and very atypical conformation is probably explained by the present of the residue Ala106, instead Asn106 or Ser106, which are conserved in beta-lactamases (Figure <ref type="figure">5</ref>). Overall, thee key elements of the active site exhibited a positioning, which lead to an enlargement of the active site. This enlargement can explain the activity of BES-1 against the bulky wide-spectrum β-lactams.</p><p>At last, the residue Arg220 establishes hydrogen bonds with the hydroxyl group of residues 236 and 245 and with the lateral chain of Thr237 (Figure <ref type="figure">6</ref>). This conformation of Thr237 could favor accommodation of carboxylic group of cephalosporins.</p><p>This first structure of BES-1 provided very interesting data which explain the atypical activity of BES-1. To confirm, these preliminary results Arg220Ala and Ala106Asn BES-1 mutants have been constructed and have been analyzed by enzymatic method. The two mutants exhibited a decrease of activity against wide-spectrum βlactams and the mutant Arg220Ala loosed the resistance to the β-lactamase inhibitor tazobactam. We are planning to investigate these mutants by X-ray diffraction to show the structural consequences of these substitutions and make the "story" complete. BES-1 in green TEM-1 in purpule Glu166 Ser70 R é sidu 237 R é sidu 238 R é sidu 240 R é sidu 241 R é sidu 242 R é sidu 243 R é sidu 244 R é sidu 245 BES -1 TEM -1 CTX -M -9 Glu166 Ser70 R e sidue 237 Re sidue 238 R e sidue 240 Residue 241 R e sidue R e sidue 243 R e sidue 244 R é sidu 245 Figure 3 BES-1 in green TEM-1 in purpule CTX-M-9 in yellow 245 102 234 Ser70 106 105 166 170 244 240 235 236 237 238</p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><figDesc>Figure 2</figDesc></figure>
		</body>
		<back>
			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0"><p>Figure <ref type="figure">5</ref> BES-1 in green TEM-1 in purpule CTX-M-9 in yellow</p><note type="other">Figure 6</note><p>Lys234</p></div>			</div>
			<div type="references">

				<listBibl/>
			</div>
		</back>
	</text>
</TEI>
